NNV-024

N/A

Report date: 2025/06/11 11:14:47

Base Information

Drug NameNNV-024
Drug Alias Namehumanized anti-CD37 monoclonal antibody (Nordic Nanovector)NNV-023NNV-025NNV-024NNV-032
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLeukocyte antigen CD37 antagonists
TargetsLeukocyte antigen CD37
Therapy Area/IndicationsAutoimmune DiseasesLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorway
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNordic Nanovector Asa
China Registration ClassN/A

Develop Information

Active CompaniesNordic Nanovector Asa
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A